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ABSTRACT 
Although renal transplantation improves survival, cardiovascular morbidity and mortality 
remains significantly elevated compared to non-renal populations. The negative impact of 
traditional, uremia- and transplantation-related risk factors in this process remains, however, 
largely unexplored. Surrogate markers like aortic stiffness and central wave reflections may lead 
to more accurate cardiovascular risk stratification, but outcome data in renal transplant recipients 
are scarce. We aimed to establish the prognostic significance of these markers for fatal and non-
fatal cardiovascular events in renal transplant recipients. Carotid-femoral pulse wave velocity, 
central augmentation pressure and central augmentation index were measured in a cohort of 512 
renal transplant recipients using the SphygmoCor-system. After a mean follow-up of 5 years, 20 
fatal and 75 non-fatal cardiovascular events were recorded. Using receiver operating 
characteristic curves, the area under the curve for predicting cardiovascular events was 0.718 
(95%CI: 0.659-0.776) for pulse wave velocity, 0.670 (95%CI: 0.604-0.736) for central 
augmentation pressure and 0.595 (95%CI: 0.529-0.660) for central augmentation index. When 
accounting for age, gender and C-reactive protein in Cox-regression analysis, pulse wave velocity 
(HR: 1.136 per m/s increase; 95%CI: 1.050-1.228; P=0.001) and central augmentation pressure 
(HR: 1.048 per mmHg increase; 95%CI: 1.024-1.073; P<0.001) remained independent predictors 
of outcome. Aortic stiffness and increased wave reflections are independent predictors of 
cardiovascular events in renal transplant recipients. As single parameter of wave reflection, 
central augmentation pressure was better than central augmentation index. Combined 
measurement of pulse wave velocity and central augmentation pressure may contribute to an 
accurate cardiovascular risk estimation in this heterogeneous population.  
2 
 
Key Words: cardiovascular events, mortality, pulse wave velocity, augmentation pressure, 
augmentation index, transplantation, kidney 
Introduction 
Although the survival advantage offered by successful renal transplantation 1 for a large part can 
be attributed to a long-term reduction of the cardiovascular (CV) disease progression and 
mortality 2, the annual risk of CV death still remains about 50-fold higher than in the general 
population 3. Nevertheless, CV death rates in transplanted patients are reduced by approximately 
75% compared to wait-listed patients remaining on dialysis 4. This decrease in CV risk by partial 
restoration of kidney function can be offset by the emergence or worsening of other risk factors 
due to transplant-specific causes such as acute rejection, infection, or side effects of 
immunosuppressive drugs, including new onset diabetes after transplantation (tacrolimus, 
steroids), dyslipidemia (calcineurin inhibitors, mammalian target of rapamycin (mTOR) 
inhibitors), and anemia (mTOR inhibitors). Part of the CV risk after transplantation may also 
relate to irreversible vascular damage accrued during the pre-transplantation period.  
These numerous potential risk factors together with the small number of randomized trials 
renders the management of CV risk in renal transplant recipients (RTR) particularly difficult 
while this population represents one of the largest groups of patients with chronic kidney disease 
(CKD) regularly seen by the nephrologist. Therefore, surrogate markers of arterial damage like 
aortic stiffness and central wave reflections have gained increasing interest for the assessment of 
overall CV risk in this heterogeneous population. Patient and donor characteristics that have been 
related to measures of arterial stiffness and/or wave reflection include donor age 5, graft function 
6, 7, micro-inflammation 7, new onset diabetes after transplantation 8, hypomagnesemia 9 and use 
of cyclosporine 10. However, these cross-sectional relationships are only relevant if the presumed 
(extrapolated) prognostic significance of these indices is confirmed by outcome data within this 
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specific population. Apart from one recent study on the predictive value of PWV 11, prospective 
data with hard endpoints in RTR remain scarce, particularly for parameters of wave reflection. 
Therefore, in the present study we aimed to establish the prognostic significance of parameters of 
wave reflection when combined with PWV, for the occurrence of fatal and non-fatal CV events 
in a large cohort of RTR. 
 
Methods 
Patients 
The study was conducted at two university hospitals in the Belgian cities of Ghent and Brussels. 
All prevalent RTRs with a functional graft attending the outpatient clinics of the Ghent 
University Hospital (Ghent) and the Saint-Luc Academic Hospital (Brussels) between February 
1st 2004 and January 31st 2006 were eligible for the study. Inclusion criteria were age ≥18 years 
and time after transplantation ≥3 months. Combined organ transplants and patients under 
treatment for malignancy (except nonmetastatic cutaneous cancers) were excluded. The study 
was approved by the Local Research Ethics Committees and written informed consent was 
obtained from each participant. 
 
Assessment of Arterial Stiffness and Wave Reflection 
All measurements were performed by two trained investigators (Ghent: F.V.; Brussels: P.N.). 
Blood pressure was recorded in the dominant or non-fistula arm using a validated oscillometric 
device (Omron M4-I; Omron Corporation, Japan). Radial artery pressure waves were obtained 
from applanation tonometry with a high-fidelity micromanometer (SPC-301, Millar Instruments), 
calibrated on the brachial systolic and diastolic blood pressure. From these radial waveforms, a 
corresponding central wave was reconstructed by the application of a validated generalized 
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transfer function 12 (SphygmoCor software version 7, AtCor Medical). The integral system 
software calculated the central augmentation pressure (CAP) as the difference between the 
second and first systolic peaks, and the central augmentation index (CAI) as CAP divided by 
central pulse pressure (CPP). 
 Aortic pulse wave velocity (PWV) was measured with the same device by sequentially 
recording ECG-gated carotid and femoral artery pressure waves, using the intersecting tangent 
algorithm to determine the characteristic points. The path length was calculated as 80% of the 
direct distance measured between the carotid and femoral measurement sites, as recommended by 
the Reference Values for Arterial Stiffness’ Collaboration group 13.  PWV was calculated as the 
path length divided by transit time (m/s). 
 
Laboratory measurements 
Hematocrit and serum levels of calcium, phosphorus, total cholesterol, HDL cholesterol and 
parathyroid hormone were determined using standard methodology. High sensitivity C-reactive 
protein (CRP) was measured with the Roche particle-enhanced immunoturbidimetric assay 
(Roche Diagnostics GmbH, Mannheim, Germany) at one site and with the Dade-Behring 
nephelometric assay (Dade-Behring, Deerfield, Ill., USA) at the other. Deming regression 
analysis has been shown good concordance between these 2 assays 14. 
 
Follow-up 
Patients were followed for the occurrence of fatal and non-fatal CV events, recorded from review 
of hospital medical charts and systematic telephone contact with each referring nephrologist. CV 
events were defined as myocardial infarction, coronary revascularization, acute pulmonary 
edema, stroke, transient ischemic attack, revascularization for peripheral vascular disease or 
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aortic aneurysm, and sudden death. When multiple events occurred in the same patient, only the 
time to the first event was analyzed. 
 
Statistical Analysis 
Data are presented as means, medians, or percentages as appropriate. Differences in risk factors 
between patients with and without an event were tested using the χ2 statistic for discrete variables 
and the t test or the Wilcoxon rank-sum test for continuous variables, depending on the 
distribution. Receiver operating characteristic (ROC) curves were used to compare the 
discriminative power of PWV, CAP and CAI when used as a single parameter to predict 
outcome. Kaplan-Meier cumulative-event curves according to tertiles of PWV and CAP were 
constructed to describe the frequency of events according to time since baseline measurements 
and compared by the Mantel (log-rank) test.  
 Hazard ratios (HRs) and their 95% confidence intervals (CI) were calculated using Cox 
proportional hazards models to estimate the independent relationship with outcome of PWV and 
CAP/CAI, analyzed as continuous variables. The parameter of wave reflection included in the 
final model was based on statistical criteria where CAP and CAI were allowed to compete in a 
stepwise Cox-regression procedure that also included PWV, age, and gender. After forcing PWV, 
CAP, age and gender into the model, we allowed any of the following variables to enter the 
model in a stepwise forward selection procedure based on the likelihood ratio test: center, length, 
weight, body mass index, current smoking status, diabetes, mean arterial pressure, heart rate, time 
after transplantation, hemoglobin, serum calcium, phosphorus, calcium-phosphorus product, 
parathyroid hormone, total cholesterol, HDL cholesterol, C-reactive protein, treatment with ACE-
inhibitors or angiotensin-receptor blockers, statins, and cyclosporine. Analyses with and without 
history of CV disease were compared to verify the consistency of our results. We chose not to 
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include CV history in the final model because (1) it is a rather crude dichotomous measure 
lacking information on type, number of events, and timing in relation to the start of the study; and 
(2) the validity of a statistical model that contains a variable that at the same time is a predictor of 
outcome and an outcome parameter as such may be questioned.The model assumption of 
proportionality of hazards was verified by plotting the partial residuals against time and testing 
for models including time-dependent covariates.  
 In a secondary analysis, we assessed the predictive value and discrimination of models 
based on standard CV risk factors with and without PWV and CAP. The selection of covariates 
was based on the components of the European SCORE project and included: age, gender, total 
cholesterol, current smoking and systolic blood pressure. The predictive value of the different 
models was assessed by using the likelihood ratio test, the Akaike information criterion and the 
Bayesian information criterion; the latter 2 tests account for the number of predictors in the 
model. For all models, we computed the C statistic as the area under the ROC curve of predicted 
probabilities. We also computed net reclassification improvement using three categories of risk. 
Cut points for different categories were obtained as follows. First we computed predicted risk for 
all patients using a Cox model that included only standard risk factors. Using these predicted 
risks, we then defined cut points for risk groups based on tertiles of predicted risk in patients who 
experienced an event within 5 years, resulting in a uniform distribution of events across risk 
categories. We cross-classified risk categories based on the model that only included standard 
risk factors against those based on the model that added PWV and CAP. Cross-classification was 
assessed separately in patients who did or did not experience an event. Statistical analyses were 
performed with SPSS 15.0 software and all tests were two-sided. 
 
Results 
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Between February 2004 and February 2006, 512 RTR were included. Most patients were 
caucasian (98%) and maintenance immunosuppressive regimens consisted of various 
combinations of azathioprine (25%), mycophenolate mofetil (55%), cyclosporine (47%), 
tacrolimus (35%) and/or sirolimus (12%). Steroids were part of the immunosuppressive regimen 
in 84% of patients. After a mean follow-up of 5 years, 20 fatal and 75 non-fatal CV events were 
recorded. Table 1 shows the characteristics and hemodynamic parameters of patients with and 
without events.  
 Using ROC-curves, the area under the curve (AUC) for predicting CV events was 0.718 
for PWV, 0.670 for CAP and 0.595 for CAI (figure 1). Based on the numerically better AUC for 
CAP as compared to CAI, the former parameter of wave reflection was used to construct survival 
curves. Unadjusted Kaplan–Meier cumulative-event curves according to tertiles of PWV and 
CAP are shown in figure 2. 
 In multivariate Cox-regression analysis including age, gender and PWV, the stepwise 
regression procedure preferred CAP over CAI as variable of wave reflection. C-reactive protein 
was an additional independent predictor of outcome. Both PWV and CAP independently were 
associated with an increased risk for a first CV event with a HR of 1.35 (95% CI: 1.10 to 1.65; 
P=0.003) and 1.49 (95% CI: 1.22 to 1.81; P<0.001), per SD increase in PWV and CAP, 
respectively. The final model is displayed in table 2. Including history of CV disease in the 
multivariate Cox-regression model had only a minor effect on the parameter estimates of CRP, 
PWV and CAP without changing the overall conclusions (data not shown). No center effect was 
observed, and forcing center into the model did not alter the regression coefficients of the other 
covariates (data not shown). 
 When PWV and CAP was added to a base model that included age and sex, measures of 
model performance improved to a degree that was slightly better than adding the full set of 
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standard risk factors to the base model (table 3). The addition of PWV and CAP to the risk factor-
adjusted model resulted in a further improvement of model fit as indicated by reductions in log 
likelihood, the Akaike information criterion and the Bayesian information criterion. The C 
statistic increased with 1% from 0.781 to 0.791. The addition of PWV and CAP resulted in 
upward reclassification of 14.7% of patients who experienced an event and a downward 
reclassification of 1.2% of patients who did not experience an event, yielding a net 
reclassification improvement of 15.9% (P=0.03; table 4). 
 
Discussion 
In contrast to the abundance of cross-sectional studies on arterial stiffness and wave reflections in 
renal populations, only a paucity of outcome data are currently available and if any, they mostly 
refer to PWV (only) and to dialysis populations 15, 16. The present study provides the first direct 
evidence in RTR that not only aortic stiffness but also central wave reflection are predictors for 
fatal and nonfatal CV events, extending the available evidence from the dialysis population to 
patients with a kidney transplant. It is also the first study to confirm in non-dialyzed patients, that 
stiffness and wave reflection both contribute independently to adverse central hemodynamic 
effects as has been shown in hemodialysis patients 17. Therefore, the results of the present study 
support the recommendation of an expert consensus document to measure as well PWV as pulse 
wave analysis derived parameters (such as CAP and CAI) to determine the contribution of aortic 
stiffness to wave reflections 18, 19. Finally, we also demonstrated that prognostic value of CAP as 
parameter of wave reflection is numerically and statistically superior to CAI. This may have 
several reasons. First, because CAI is calculated as CAP/CPP, the resulting index is not only 
determined by wave reflection (CAP) but also by proximal aortic compliance and stroke volume 
(CPP). Second, in contrast to the linear age-related increase of CAP, changes in CAI with ageing 
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are non-linear and more prominent under 50 years of age 7, 20 which is an analytical disadvantage 
when age related effects have to be accounted for in statistical modeling. Third, CAI is a 
calculated dimensionless parameter that may be negative, whereas CAP is a measured pressure 
that allows a more straightforward interpretation. 
Although aortic stiffness and peripheral wave reflections both lead to an increased CPP, which is 
the resulting pulsatile load to the myocardium, discrimination between these two mechanisms 
may be relevant for prognostic and therapeutic reasons. A high CPP due to an increased aortic 
PWV indicates a loss of cushioning function of the central (proximal) aorta, whereas a high CPP 
due to pressure augmentation (but with a normal PWV) rather points to a disturbance at a more 
distant level in the circulation resulting in an increased peripheral resistance.  
 Overall, mean values of PWV and CAP may seem somewhat lower than those reported in 
other high risk populations. This may due to the fact that RTR are a selected group of patients 
considered suitable for transplantation based on prior cardiovascular evaluation. Also, absolute 
values of PWV should be interpreted in relation to blood pressure, which was well controlled in 
the present cohort. Nevertheless, it has been shown that these parameters are significantly higher 
compared to healthy controls, matched for age, gender and blood pressure 7. The underlying 
mechanisms contributing to arterial stiffening and increased wave reflection are complex and 
incompletely understood. In RTR, in addition to the adverse effects of immunosuppressive drug 
regimens on traditional CV risk factors, specific transplantation-related mechanisms have been 
implicated in subclinical damage of the large arteries. An independent relationship between level 
of transplant kidney function and indices of arterial stiffness 7, 21 has been reported, suggesting a 
role of uremic retention solutes with known vasculotoxic effects such as homocysteine, 
asymmetric dimethylarginine, inorganic phosphate, phenylacetic acid or dinucleoside 
polyphosphates 22. More recently, a direct link between decreased serum levels of Fetuin-A, a 
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calcification inhibitor, aortic calcification and CV outcome has been demonstrated in RTR 23. 
Increasing evidence supports the hypothesis that medial wall calcification is an important factor 
contributing to aortic stiffness, although studies comparing both calcification and stiffness in 
RTR are not available. Calcineurin inhibitors, still a cornerstone in many immunosuppresive drug 
regimens, exert dose-dependent renal and systemic vasoconstrictive effects and may increase 
peripheral wave reflection 10. A remarkable independent association between donor age and PWV 
has been reported by Delahousse et al.5. We did not evaluate donor age as transplant kidney 
allocation in our unit is influenced by active matching between donor and acceptor age, thus 
creating collinearity.  
We previously reported an independent relationship between high sensitivity CRP and 
PWV/AI 7. In the present study, high sensitivity CRP remained an  independent predictor of CV 
events, indicating that the adverse effect of microinflammation is only partially explained by its 
relationship with pulsatile hemodynamics. Low-grade inflammation in RTR may represent a 
residual effect from before transplantation and/or be due to other sources than those encountered 
in the dialysis stage, such as chronic allograft nephropathy 24, periodontal disease 25 or treatment 
with sirolimus 26. In view of the adverse impact of subclinical inflammation, these sources should 
be searched for and remediated if present. Besides specific sources of inflammation, 
microinflammation may also be primarily an indicator of sustained arterial damage due to 
atherosclerosis. This is supported by a study of Varagunam et al. 27 where pre-transplantation 
CRP was an independent predictor of CV and all-cause mortality after transplantation.  
In contrast to other populations, in the current cohort of RTR, smoking status and total 
cholesterol were not independent predictors of outcome, whereas CRP emerged as a strong 
predictor in all models. Moreover, the addition of PWV and CAP to a model based on the 
components of the SCORE risk chart improved discrimination and net reclassification. This is not 
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unexpected as risk score algorithms such as the Framingham Risk Score and the corresponding 
European SCORE system have never been validated in renal populations. Therefore, clinicians in 
charge of RTR should resist the temptation to estimate risk based on (components of) these risk 
scores. On the other hand, our data are in line with recent population-based studies in subjects 
without prior CV disease, showing that risk prediction is improved when adding PWV to these 
risk scores 28, 29. 
The present study had several limitations. We studied a prevalent cohort of patients with 
variable time since transplantation and no data on PWV or CAP/CAI from before transplantation 
were available, but obtaining longitudinal data would have taken considerably more time to come 
to relevant results. The majority of our patients received a cadaveric kidney so that care should be 
taken in extrapolating the results to acceptors of living donation. Finally, this was a non-
interventional study so that treatment effects could not be evaluated. Nevertheless, it should be 
noted that the predictive value of PWV and CAP/CAI was not affected by type of 
immunosuppressive regimen, previous kidney transplantation, or living versus cadaveric 
transplant. The calibration of radial pressure waveforms with brachial artery pressures as 
advocated in the user manual of the Sphygmocor device, may lead to some error in the 
assessment of central blood pressure and central augmentation pressure 30. Since this error is 
present in all patients data and is expected to be proportional, it will not influence the conclusions 
of the present study. On the other hand, the strengths of our study include the large patient 
number, the use of non-invasive methodology, and the strong and independent predictive value of 
the obtained parameters for adverse outcome in this particular population. 
 
Perspectives 
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Carotid-femoral PWV and CAP provide complementary predictive information for  the 
occurrence of fatal and nonfatal CV events in RTR, and may help to identify patients at high risk. 
In such patients, traditional risk factors should be treated aggressively and immunosuppressive 
drugs with less direct or indirect vasculotoxic side effects should be preferred. These patients 
may also require more regular preventive diagnostic CV evaluation. In patients at low CV risk 
according to PWV and CAP, the more common immunologically directed approach focused on 
minimizing the risk of rejection may be more appropriate. Additionally, these parameters may 
also improve stratification according to baseline CV risk in interventional trials, and thus may 
serve both scientific as well as clinical purposes. Major advantages over several other potential 
surrogate markers are the non-invasive nature of the technique, the minor discomfort for the 
patient, the limited time needed to obtain the measures, and the relatively low cost compared to 
traditional ultrasonographic or radiographic equipments. The outcome data of the present study 
further add to the rapidly accumulating evidence on the strong, consistent and independent 
predictive value of these measures for hard endpoints and support the adoption of PWV as 
marker of target organ damage in the most recent ESH guidelines 31. Future studies should 
determine the optimal cutoff-values in specific populations such as RTR, and provide thresholds 
for diagnostic and/or therapeutic interventions such as changing the immunosuppressive regimen. 
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TABLE 1. Baseline characteristics according to outcome 
 
Variable No event Event† P 
Age (years) 51.5 60.8 <0.001 
Male gender (%) 54.0 78.9 <0.001 
Diabetes (%) 12.7 27.4 <0.001 
Smoking (%) 12.3 13.7 0.7 
Pos. CV history (%) 22.8 68.4 <0.001 
Living donor (%) 9.6 8.4 0.7 
Transplant time (years) 7.7 7.2 0.5 
    
Body Mass Index (kg/m2) 25.9 26.9 0.07 
Hemoglobin (g/dL) 12.9 12.8 0.9 
MDRD (mL/min) 53.3 53.4 0.9 
Calcium (mg/dL) 9.6 9.6 0.4 
Phosphorus (mg/dL)  3.1 3.1 0.7 
PTH (pg/mL)* 48 63 0.001 
Total Cholesterol (mg/dL) 208 205 0.5 
HDL Cholesterol (mg/dL) 61 58 0.14 
CRP (mg/L)* 1.8 3.3 <0.001 
    
SBP (mmHg) 132.7 144.4 <0.001 
DBP (mmHg) 79.6 79.8 0.9 
MAP (mmHg) 98.1 102.2 0.03 
Heart rate (min-1) 64.5 65.1 0.6 
PWV (m/s) 9.2 11.2 <0.001 
CAP (mmHg) 12.2 17.7 <0.001 
CAI (%) 41.4 49.7 0.005 
 
Legend: PTH = parathyroid hormone; CRP = C-reactive protein; PWV = pulse wave velocity ; 
CAP = central augmentation pressure ; SBP = systolic blood pressure ; DBP = diastolic blood 
pressure ; MAP = mean arterial pressure; * median value 
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† Numbers of events (fatal+non-fatal): 13+38 cardiac; 2+10 cerebral; 5+27 peripheral 
 
TABLE 2. Cox-regression models of factors predicting CV events 
 
Legend: CRP = C-reactive protein; PWV = pulse wave velocity; CAP = central augmentation 
pressure; SBP = systolic blood pressure; PTH = parathyroid hormone; MAP = mean arterial 
pressure 
 Variable (1 SD) HR 95% CI P 
 
Model 1 
 Age (12.8 years) 1.679 1.242 – 2.270 0.001 
 Gender (Male=1) 2.702 1.607 – 4.542 <0.001 
 CRP (8.6 mg/L) 1.276 1.132 – 1.438 <0.001 
 PWV (2.7 m/s) 1.349 1.104 – 1.649 0.003 
 CAP (8.6 mmHg) 1.487 1.219 – 1.814 <0.001 
       
Model 2: Model 1 plus 
 SBP (19.6 mmHg) 1.129 0.849 – 1.501 0.404 
 Total Cholesterol (42 mg/dL) 0.985 0.781 – 1.242 0.898 
 Smoking (Yes=1) 1.557 0.802 – 3.023 0.191 
       
Model 3: Model 2 plus 
 Diabetes (Yes=1) 1.329 0.763 – 2.314 0.316 
 Body Mass Index (4.8 kg/m2) 0.992 0.798 – 1.233 0.943 
 PTH (83 pg/mL) 1.043 0.859 – 1.265 0.672 
 MAP (13.3 mmHg) 0.943 0.625 – 1.422 0.779 
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TABLE 3. Measures of model fit and discrimination for various cardiovascular event 
models without and with PWV and CAP 
 
  Model Fit  Discrimination 
 
Model 
-2 Log 
Likelihood 
Akaike  
Information Criterion 
Bayesian  
Information Criterion 
C Statistic  
(95% CI) 
     
Age, sex 424 430 442 0.750 (0.698-0.803) 
Age, sex, PWV and 
CAP 
375 385 406 0.784 (0.731-0.837) 
Age, sex, SBP, total 
cholesterol, smoking 
407 419 445 0.781 (0.730-0.832) 
Age, sex, SBP, total 
cholesterol, smoking, 
PWV and CAP 
370 386 420 0.791 (0.739-0.843) 
 
Legend: PWV = pulse wave velocity; CAP = central augmentation pressure; SBP = systolic 
blood pressure 
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TABLE 4. Predicted risk for a CV event before and after reclassification with PWV and 
CAP in patients who did (A) and did not (B) experience an event within 5 years 
 
  Model with PWV and CAP  
A  <20% 20-40% >40% Total 
Model without PWV and CAP     
 <20% 27* 5 0 32 
 20-40% 1 15* 14 30 
 >40% 0 4   29* 33 
Total  28 24 43 95 
      
B  <20% 20-40% >40% Total 
Model without PWV and CAP     
 <20% 298* 10 0 308 
 20-40% 20   49* 10 79 
 >40% 0 5   25* 30 
Total  318 64 35 417 
 
*These values along the diagonal were classified similarly by both models. Values on each row 
to the right of values with an asterisk were upwardly classified, and those to the left were 
downwardly classified by the model that included PWV and CAP.  
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FIGURE LEGENDS 
 
Figure 1.  
Receiver operating characteristic (ROC) curves for PWV, CAP and CAI when used as a single 
parameter to predict outcome. Area under curves (AUC) with 95% confidence intervals are 
displayed (all significant different from AUC=0.5; P<0.001) 
 
Figure 2. 
Unadjusted Kaplan–Meier cumulative-event curves for first fatal or non-fatal cardiovascular 
event according to tertiles of (A) PWV and (B) CAP. The differences among all curves were 
statistically significant (P<0.001). 
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